GTx Files Toremifene For Prostate Cancer-Related Bone Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.
You may also be interested in...
Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.
Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.
Amgen Submits Denosumab BLA Ahead Of Expectations
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.